GoldenGolden
Advanced Search
BIND Therapeutics

BIND Therapeutics

A nanomedicine company that develops Accurins for targeted therapeutics

BIND Therapeutics was a Cambridge, Massachusetts-based biotechnology company specializing in the development of accurins for application in novel therapeutic solutions. The company was founded in 2006 by Robert Langer and Omid Farokhzad. Following its bankruptcy, Pfizer acquired most of BING Therapeutics' assets.

Timeline

February 2013
BIND Therapeutics raises a $8,700,000 venture round.
February 2012
BIND Therapeutics raises a $25,500,000 series D round from Rusnano.
October 2011
BIND Therapeutics raises a $4,800,000 venture round.
June 2010
BIND Therapeutics raises a $12,400,000 series C round from ARCH Venture Partners, Endeavour Vision, Flagship Pioneering, NanoDimension and Polaris Partners.
November 2007
BIND Therapeutics raises a $16,000,000 series B round from ARCH Venture Partners, Flagship Pioneering, NanoDimension and Polaris Partners.
February 2007
BIND Therapeutics raises a $2,500,000 series A round from Flagship Pioneering and Polaris Partners.

Funding rounds

People

Name
Role
LinkedIn

Ben Narlee

Employee

Megan Bishoff

Employee

Michelle Minick

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.